Anocca AB, a T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, and EmendoBio Inc., a nuclease discovery and gene editing therapeutics company, have entered a non-exclusive licensing agreement for the use of EmendoBio’s novel OMNI-A4 nuclease to accelerate the manufacture and development of Anocca’s pipeline of TCR-T cell therapies for difficult-to-treat solid cancers.   “Integrating EmendoBio’s nuclease into our manufacturing process supports Anocca’s aim of generating t...